Effect of Trimetazidine Dihydrochloride Tablets adjuvant therapy on inflammatory reaction, oxidative stress, vascular endothelial function and myocardial function in patients with coronary heart disease complicated with heart failure
Cai-wen Wei,Zhi-hua Li,Lei Song,Da-min Huang,Ying-min Lu,Xiao-han Luo
DOI: https://doi.org/10.13210/j.cnki.jhmu.20171027.004
2017-01-01
Abstract:Objective:To investigate the effects of Trimetazidine Dihydrochloride Tablets on inflammatory reaction,oxidative stress,vascular endothelial function and myocardial function in patients with coronary heart disease complicated with heart failure.Methods:98 patients with coronary heart disease and heart failure who met the criteria of the study were selected as the subjects,based on the random data table they were divided into the control group (n =49) and observation group (n =49),the patients in the control group were treated with Metoprolol Tartrate Sustained release Tablets treatment,and the patients in the observation group were treated with Metoprolol Tartrate Sustained-release Tablets combined with Trimetazidine Dihydrochloride Tablets,the levels of inflammatory reaction,oxidative stress,vascular endothelial function and myocardial function indexes were compared between the two groups before and after treatment.Results;The difference of the CRP,TNF α,MDA,SOD,NO,ET-1,LVEF,LVEDD and LVESD levels in the two groups before treatment were not statistically significant (P＞0.05);Compared with the levels of the two groups before treatment,the two groups of CRP,TNF-α,MDA,ET-1,LVEDD and LVESD levels after treatment were significantly decreased,and the level of the observation group after treatment was significantly lower than those levels in the control group,the difference was statistically significant (P＜0.05);The levels of SOD,NO and LVEF of the two groups after treatment were significantly higher than those in the same group before treatment,and the observation group levels [(88.09±7.51) U/mL,(72.58±14.64) mol/L,(48.34±5.09)％] were significantly higher than the control group [(79.44±7.27) U/ml,(61.89±11.06) mol/L,(44.19±4.58)％],the difference was statistically significant (P＜0.05).Conclusion:Trimetazidine Dihydrochloride Tablets in the treatment of coronary heart disease with heart failure can effectively inhibit the release of inflammatory factors,improve oxidative stress state,vascular endothelial function and myocardial function,has an important clinical value.